微卫星不稳定性
一致性
免疫组织化学
转移
多路复用
结直肠癌
肿瘤科
DNA错配修复
医学
内科学
腺癌
癌症
癌症研究
病理
微卫星
生物信息学
生物
遗传学
基因
等位基因
作者
Paola Parente,Umberto Malapelle,Valentina Angerilli,Mariangela Balistreri,Sara Lonardi,Salvatore Pucciarelli,Caterina De Luca,Francesco Pepe,Gianluca Russo,Elena Vigliar,Angela Danza,Fabio Scaramuzzi,Giancarlo Troncone,Paolo Graziano,Matteo Fassan
标识
DOI:10.1136/jclinpath-2022-208143
摘要
Mucinous adenocarcinoma (MA) is associated with a high frequency of microsatellite instability (MSI). In the metastatic setting, it is crucial to establish mismatch repair (MMR) and/or MSI status. However, genetic heterogeneity between primary tumour and synchronous metastasis and the diagnostic accuracy of the assay may hamper the MMR/MSI status evaluation.In this study, we assessed the concordance rate of the MMR/MSI status between primary tumour and paired synchronous metastasis of 25 MAs. MMR status was evaluated by immunohistochemistry (IHC), while MSI status was evaluated by using three different molecular approaches: microfluidic electrophoresis of PCR products (TapeStation 4200 platform), full-closed RTqPCR system (Idylla system) and multiplex amplification with fluorescent primers and subsequent DNA fragment analysis on an automated sequencer (Titano MSI test).The concordance rate between primary MA and metastasis was 21/21 (100%), 23/25 (92.0%), 23/25 (92.0%) and 21/25 (84%) by using IHC, Idylla system, Titano MSI test and TapeStation 4200 system. All the four methods used in our study displayed high concordant rate, ranging from 91.0% (IHC vs Tapestation 4200 platform) to 98.0% (IHC vs Titano).Several methodologies are frequently adopted in routine practice to successfully perform MMR/MSI status analysis. The most relevant issues related to MMR/MSI status analysis in MAs concern with low percentage of neoplastic cell and abundant mucine that may affect the molecular analysis. Thus, it might be useful to acquire both primary and metastatic sample to evaluate the MMR/MSI status by integrating IHC evaluation and molecular methodologies to successfully perform molecular profiling for MA patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI